Publications by authors named "Shi-Hong Zhou"
Article Synopsis
- * Standard treatment for early-stage MTC is surgery, with a 10-year survival rate over 80%, while metastatic cases face lower survival rates (10-40%) and limited effective therapies.
- * Recent advancements in targeted therapies, particularly RET inhibitors like Cabozantinib, Vandetanib, Selpercatinib, and Pralsetinib, offer new hope, though challenges such as drug resistance and side effects still complicate treatment for advanced MTC.
Background: Cumulative preclinical and clinical evidences showed radiotherapy might augment systemic antitumoral responses to immunotherapy for metastatic non-small cell lung cancer, but the optimal timing of combination is still unclear. The overall infiltration and exhausted subpopulations of tumor-infiltrating CD8 T cells might be a potential biomarker indicating the response to immune checkpoint inhibitors (ICI), the alteration of which is previously uncharacterized during peri-irradiation period, while dynamic monitoring is unavailable via repeated biopsies in clinical practice.
Methods: Basing on tumor-bearing mice model, we investigated the dynamics of overall infiltration and exhausted subpopulations of CD8 T cells after ablative irradiation.